- Table of Contents
We validate the specificity of these antibodies to SOX10 by testing them on tissues known to express SOX10 positively and negatively. Browse below to find the SOX10 antibody that suites your experiment. We have 6 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about Transcription factor SOX-10.
Once induced, MYRF cooperates with SOX10 to execute the myelination program. Transcriptional activator of MITF, acting synergistically with PAX3 (PubMed:21965087).
DOM; MGC15649; PCWH; SOX10; SRY (sex determining region Y)-box 10; SRY-related HMG-box gene 10; transcription factor SOX-10; WS4; WS4C; WS4mouse, human homolog of
|Sequence:||22; NC_000022.11 (37972312..37984555, complement)|
Expressed in fetal brain and in adult brain, heart, small intestine and colon.
Cytoplasm. Nucleus. Mitochondrion outer membrane; Peripheral membrane protein; Cytoplasmic side.
When you're researching SOX10 protein, you need to be aware of the products, applications, and references of the company Boster Bio. This article will give you an overview of Boster Bio's SOX10 anti transcription factor antibody. Apart from its numerous applications, this antibody comes with several other benefits, which you will learn about by reading further. Boster Bio Anti-Transcription Factor SOX10 antibody is available for purchase. It has been tested for use in IF, WB and ICC applications.
Boster Bio is a specialist in a range of polyclonal antibodies aswell as picogram sensitivity ELISA kits kits. Its antibody library includes over 12,000 primary antibodies that have been validated quantitatively as well as qualitatively to be used in IHC, WB and Flow applications. The antibodies are tested against untransfected tissues and cells. The resulting antibodies are highly specific and have high affinity.
Boster Bio offers the anti-SOX10 antibody in ELISA and IF formats. The antibody reacts with Human, Mouse, and Rat. It can also be purchased as an peptide that blocks. This means that you can be certain that the anti-SOX10 antibody works across multiple platforms, ranging from one sample to many. Boster antibodies can be used on a variety of platforms to obtain more precise results.
This ELISA antibody is highly specific and can detect the presence of SOX10 in different cell types. This marker can be used to determine the presence of cells within the glial tissue using the confocal microscopy at 400 millimeters. The SOX10 protein is found in healthy tissues, but it is not found in cancerous cells. The DM+A, DM+B and the DM+B group showed greater SOX10 expression than the DM group. The DM +B group had significantly higher expression of SOX10 than the DM groups.
The products of the SOX10 marker are proteins that play crucial roles in neural crest cell development. In the process of induction of neural crest cells, SOX10 deficiency leads to a developmental bias toward nonneural ectodermal cells. The exact mechanisms behind these differences are not known. It is thought that SOX10 knockout hiPSC lines are useful tools for understanding the role of SOX10 in human NC.
A genetic screen identified the existence of a dimeric SOX10 binding pattern with 150 bases downstream of the TSS of Chn2 exon 1.D. This region is found to be conserved in vertebrates, but not in all species. We then examined an orthologous 844-base pair region in luciferase reporter assays. CHN2 Prom 4 produced 10 times more luciferase activity compared to blank control cells. The deletion of this region significantly decreased activity.
Sox10 is found in NCSCs of vertebrates. However, its expression can vary in various models of organisms. In Xenopus laevis and zebrafish SOX10 is more abundant in the postmigratory and premigratory phases of NC development. However mice express SOX10 the most during their migration NCSCs. Human embryos also displayed a similar pattern of expression. These results suggest that the different products of the SOX10 marker could play different roles in NC development.
SOX10 is found in human tissues, primarily in paragangliomas, neurofibromas and schwannomas. SOX10 expression was not observed in any other mesenchymal or epithelial tumors. It is also absent in astrocytomas that are adnate. This is why the products of the SOX10 marker could be superior in detecting and monitoring tumors caused by SOX10-expressing cells.
The presence of genes associated with extracellular structure, the cytoskeleton's organization, and projection of cells is associated with a decrease in SOX10 gene expression. In Schwann cells, knocking out SOX10 causes a significant deposition of extracellular matrix components. However the precise mechanisms of transcription that SOX10 causes its effects is unknown. Further research will assist to identify these complex processes. The next step is to comprehend the function of SOX10 in the body.
Recent research suggests that SOX10 is highly expressed in breast, bladder and ovarian tumors. However, the exact function of SOX10 remains elusive. In 2014, Sun et al. Sun et al. (2014) published a review on SOX10's role in the development of cancer. In 2016, Kaufman and Laurette published the same review. A similar review was published by Kaufman and Seberg in 2017.
SOX10 expression is strongly associated with epithelial tumors and soft tissue tumors as demonstrated by its numerous immunohistochemical marks. At present, Sox10 antibody is included in an immunohistochemical panel for epithelial and soft tissue tumors. SOX10 has been implicated with various cancer types and soft tissue tumors which aren't malignant.
Its regulation and activation plays a critical role in neural stem cell expansion and differentiation. The SOX10 marker is becoming an increasingly important diagnostic tool. As more assistive tests are added to clinical practice, the demand for cell blockages will increase. SOX10 is therefore one of the first proteins to be able to identify cancer tumors. And as the number of diagnostic tests increase and the number of new diagnostic tests increases, the SOX10 protein will continue to play an essential role in clinical practice.
Studies have shown that SOX10 is related to cancer cells in melanoma that promote apoptosis. Mutants of SOX10 could also cause adaptive resistance to RAF inhibitors. RAF inhibitors are protected by adaptive resistance while acquired resistance is able to beat cancer cells. Incredibly, FOXD3 loss increases the cytotoxic effects of RAF inhibitors on cancer cells.
In addition to its clinical function, SOX10 is used to detect antigen-presenting cells. These cells are widespread in all tissues, however tumors can express SOX10 significantly. Thus, tumors that have SOX10 staining might be classified as being S100-positive in the focal region. It is a highly specific, consistent antigen-presenting cells marker that can be used in the diagnosis of the presence of melanoma.
While Sox10 expression is highly correlated with tumor stage, there is no consensus as to which cancer subtypes are the ones that express the protein. However, SOX10 is expressed in many types of cancer, including basal cell carcinoma and Adenoid cystic cancer. It is not clear what the underlying mechanism of these heterogeneous conditions may be. The SOX10 gene could be useful in subclassifications of Neoplasms of the skin adnexal.
The SOX10 gene is present in a variety tissues, including cancers of the major salivary glands. It has been found in salivary gland tumors in both murine studies as well as in human major salivary gland tissues. Recent research has revealed SOX10 to be a potential pathological indicator for salivary gland tumors. Studies of the molecular basis of SOX10 expression in tumors suggest that it could be a useful diagnostic tool for salivary gland malignancies.
This gene is abundantly expressed in the retina, including the outer nuclear layer. It is associated with the development of certain cancers and may also be a marker that could indicate paediatric tumours. It is interesting to note that it has recently been connected to the NC-GRN. These results suggest that SOX10 expression in the new NC cells which are often characterised by unusual behavior, is controlled.
Sox10 is part of the sex-determining region Y-related HMG-box family that is expressed in a variety of human cells. In addition to its expression in human melanocytes, it has also been shown to be a crucial marker in malignant tumors. Therefore, the detection of SOX10 in a tumor is a crucial diagnostic tool for Melanoma.
Normal salivary gland cells, mammary and bronchial tissues, and normal salivary gland cells express Sox10 however it was not expressed in serous acini. It is not found in excretory ducts that are striated or in the excretory duct. It also shows varying expression in the nerves around the acini. It is linked to epithelial stem cells in the submandibular glands of mice at embryonic days 13.5 and 14. However, its expression in salivary glands in humans is not known.
The presence of Sox10 in tumors is a reliable indicator for the progression of cancer. Although it isn't common, Sox10 can be found in tumors of the neck and head. While this gene is specific for cancers of the nervous system However, it has been proven to be confused with the expression of non-neoplastic components, like melanocytes. Keep in mind that SOX10 expression is only found in a small number of cells, therefore it should not be mistaken with cancer of the nerve sheath.